# Chiesi will launch a tender offer to buy all outstanding KalVista shares for $27.00 per share in cash.

*biotech · news · 2026-04-29 · Reuters*

## Key points

- Chiesi will acquire all KalVista shares for $27.00 each, a 36% premium over recent prices.
- The transaction is the largest acquisition in Chiesi's history and is expected to close in Q3 2026.
- KalVista's EKTERLY (sebetralstat) will support Chiesi's 2030 revenue target of 6 billion euros.
- The acquisition will expand Chiesi's US commercial presence and rare disease portfolio, especially in immunology.

**Companies:** KalVista
**Countries:** Italy, United States

[Read the full story on Reuters](https://www.reuters.com/legal/transactional/italian-pharma-group-chiesi-buy-us-peer-kalvista-19-billion-2026-04-29/)

---

Canonical: https://newsio.io/n/73cf80a2-217a-4008-af8a-0e31000de149/chiesi-will-launch-a-tender-offer-to-buy-all-outstanding-kalvista-shares-for-27
Summarized by Newsio from Reuters. https://newsio.io/how-it-works